Difference between revisions of "Combining-Valproic acid-Lamotrigine"
From Psychiatrienet
| Line 7: | Line 7: | ||
* Lamotrigine generally has no significant effect on valproate levels, however caution is recommended. | * Lamotrigine generally has no significant effect on valproate levels, however caution is recommended. | ||
* Start lamotrigine at low dose and check valproate plasma level after 1 week. Change valproate dose if necessary. <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> | * Start lamotrigine at low dose and check valproate plasma level after 1 week. Change valproate dose if necessary. <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> | ||
| + | Very slow titration of lamotrigine is recommended, because lamotrigine-related skin rashes have been reported. <ref> {{Pubmed|16225978|Chang CC at al, Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsych. Biol Psychiatry. 2006 Jan;30(1):147-50}}</ref> | ||
| + | |||
| cave = | | cave = | ||
| − | * | + | * Valproic acid increases the blood level of lamotrigine because of the inhibition of glucuronidation. Adverse reactions, particularly skin rash, may occur with greater frequency or severity. Also other side effects may occur such as ataxia, tremor, sedation, and fatigue. However, such symptoms should improve as the dose of lamotrigine is decreased.<ref name="freeman">{{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref> |
| + | * Also important, when lamotrigine is added to valproate therapy, valproate concentrations may be possibly decreased.<ref name="freeman"/> | ||
}} | }} | ||
Revision as of 10:07, 23 April 2010
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
Adding lamotrigine to valproic acid.
General information- Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
- Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
Start lamotrigine- Lamotrigine generally has no significant effect on valproate levels, however caution is recommended.
- Start lamotrigine at low dose and check valproate plasma level after 1 week. Change valproate dose if necessary. [5]
Very slow titration of lamotrigine is recommended, because lamotrigine-related skin rashes have been reported. [6]
Cave- Valproic acid increases the blood level of lamotrigine because of the inhibition of glucuronidation. Adverse reactions, particularly skin rash, may occur with greater frequency or severity. Also other side effects may occur such as ataxia, tremor, sedation, and fatigue. However, such symptoms should improve as the dose of lamotrigine is decreased.[7]
- Also important, when lamotrigine is added to valproate therapy, valproate concentrations may be possibly decreased.[7]
- ↑ 1.0 1.1 Farmacotherapeutisch Kompas; Toxicologie (dutch)
- ↑ 2.0 2.1 Farmacotherapeutisch Kompas - valproinezuur (dutch)
Cite error: Invalid
<ref>tag; name "ftk" defined multiple times with different content - ↑ KNMP; Informatorium Medicamentorum 2023; Monografie "valproaat" (Dutch)
- ↑ Drugs.com lamotrigine
- ↑ Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002.
- ↑ Chang CC at al, Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsych. Biol Psychiatry. 2006 Jan;30(1):147-50
- ↑ 7.0 7.1 Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
